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ABSTRACT 
Trials of HIV-1 pre- and post-exposure prophylaxis show promise.  Here, we describe a novel strategy for 
deciphering mechanisms of prophylaxis failure that could improve therapeutic outcomes.  A healthcare 
worker began antiretroviral prophylaxis immediately after a high-risk needlestick injury but nonetheless 
became viremic 11 weeks later.  Single genome sequencing of plasma viral RNA identified 15 drug-sensitive 
transmitted/founder HIV-1 genomes responsible for productive infection.  Sequences emanating from these 
genomes exhibited extremely low diversity, suggesting virus sequestration as opposed to low-level 
replication as the cause of breakthrough infection.  Identification of transmitted/founder viruses allows for 
genome-wide assessment of molecular mechanisms of prophylaxis failure.  
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Introduction 
Prevention of HIV-1 infection is one of the most important and challenging goals of global health.  Current 
efforts are broadly focused, and promising interventions under development include pre- and post-exposure 
prophylaxis (PrEP; PEP) using antiretroviral drugs, topical microbicides, and vaccines. Recent clinical trials 
have demonstrated efficacies of 31% to 67% for these prophylactic strategies in different risk groups [1].  
There are no prospective randomized trials of PEP, but an earlier retrospective case-control study of 
occupational exposures suggested an 81% reduction in HIV-1 acquisition [2].  Despite these encouraging 
findings, protection in all studies was incomplete.  Methodologically, it has been challenging to pinpoint 
specific mechanisms of prophylaxis failure. Nonetheless, elucidation of mechanisms of prophylaxis failure 
could aid the development of more effective regimens.  Here, we describe a novel application of the single 
genome sequencing (SGS) strategy to identify T/F viruses responsible for prophylaxis failure and implicate a 
novel mechanism of PEP treatment failure.  
 
Case Report 
A 53-year old Australian female healthcare worker (HCW) sustained a needle-stick injury with a hollow-
bore 21-gauge needle after drawing blood from an advanced stage HIV-infected patient.   She reported the 
needle pierced the pulp of her gloved index finger and that she inadvertently struck the syringe plunger such 
that a small amount of blood was likely injected.  The HCW had no other risk factors for HIV acquisition.  
The source patient had been HIV-infected for more than ten years, with prior treatment experience to three 
classes of antiretrovirals.  At the time of the exposure, he was non-adherent to his prescribed regimen of 
zidovudine, lamivudine and nevirapine.  He had a HIV viral load exceeding 100,000 copies per milliliter, a 
CD4+ T cell count of 279 cells per milliliter and a recent HIV genotype demonstrating a K103N mutation.  
The HCW initiated PEP with zidovudine, lamivudine and indinavir within two hours of the exposure and 
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completed four weeks of therapy (days 1-32) that included a four-day interruption between days 22-25.  At a 
routine visit five weeks after the needlestick exposure and several days after completing PEP treatment, the 
HCW was asymptomatic and had a negative third-generation HIV antibody ELISA test.  Eleven weeks after 
the exposure (six weeks after PEP discontinuation), the HCW presented with new onset fever, arthralgias and 
exudative pharyngitis.  Laboratory examinations revealed an HIV-1 plasma viral load of 2,200,000 copies 
per milliliter, a positive HIV-1 ELISA and an indeterminate HIV-1 Western blot (faint <1+ gp160 band 
only).  She was diagnosed with acute HIV-1 infection, Fiebig stage IV [3].   
 
METHODS 
Study subjects:  Blood samples from the index HCW and source patient were obtained after receiving 
informed consent under the Royal Perth Hospital Human Research Ethics Committee. Blood specimens were 
obtained from the HCW 81 days after exposure and from the source patient 8 days after the exposure.   
 
Viral RNA and genomic DNA extraction, cDNA synthesis, single genome amplification and direct 
sequencing:  vRNA was extracted from plasma, DNA was extracted from PBMCs, cDNA was synthesized 
from env and pol vRNA, and SGS performed as previously described [4-6]. Sequences from the index 
subject are identified throughout with the prefix 43715, and from the source subject, the prefix 43690. 
 
Sequence analysis: Sequences were aligned with ClustalW and hand-checked using MacClade 4.08. 
Phylogenetic trees were generated by the neighbor- joining (NJ) method using ClustalW or maximum 
likelihood (ML) using PhyML v.3.  Sequences were assessed for APOBEC3G/F signatures and 
recombination (see supplement for details).  
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RESULTS 
Phylogenetic Analyses 
A total of 179 full-length pol and gp41 env sequences from the HCW plasma and PBMCs and 61 
full-length pol and gp41 env sequences from the source patient plasma were determined.  Figure 1A 
illustrates a NJ phylogeny of 23 gp41 env sequences from the source patient, revealing broad genetic 
diversity (maximum 4.44%) and quasispecies complexity typical of chronic HIV-1 infection [4, 7]. Figure 
1B reveals a strikingly different pattern of env diversity in the recently infected HCW.  Here, multiple sets of 
identical or nearly identical sequences (in blue) are interspersed with sequences of recombinant origin (in 
orange). This phylogenetic pattern is characteristic of acute infection by multiple genetically diverse viruses 
[4-6], where each low diversity sequence lineage represents the progeny of a distinct T/F virus and 
interspersed viruses generally represent discrete recombinants. Occasional T/F viruses represented by a 
single sequence can also be identified based on their genetic distance from other sequences.  The two largest 
lineages among the gp41 sequences had sufficient numbers of sequences to allow for robust modeling of 
sequence diversification [4, 8].  These sequences conformed to a model of neutral evolution, including a star-
like phylogeny and a Poisson distribution of mutations (Table S1). Sequences from all low-diversity lineages 
coalesced to unambiguous T/F sequences.  Thus, we can conclude that the env sequences from the index 
subject depicted in Figure 1B represent the progeny of at least 14 discrete T/F viruses.   
These 14 T/F genomes were next analyzed together with sequences from the source patient and 
unlinked reference subjects (Fig 1C).  Source and index sequences formed a single monophyletic radiation 
supported by high bootstrap values (100%), indicating clear epidemiological linkage.  Source and index 
sequences exhibited similar maximum diversities (4.44% and 4.49%, respectively), and were interspersed in 
the phylogenetic tree, again indicating epidemiological linkage and absence of obvious selection for 
particular variants in the transmission event.  
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Figure 2 depicts the NJ phylogeny of source (A) and phylogeny and Highlighter plot of index (B) 
subjects’ viral pol sequences, which corroborate and extend findings from the env analyses.  Again, the 
pattern of sequence diversity in the chronically-infected source patient was strikingly different from that in 
the HCW, with sequences from the latter again consisting of multiple sets of identical or nearly identical 
sequences characteristic of T/F virus lineages.  As with env, the pol sequences comprising the most 
populated lineages conformed to a model of random sequence evolution (Table S1), with each lineage’s 
sequences coalescing to unambiguous T/F sequences [4].  The enumerated T/F viruses represent minimum 
estimates, which are substantially affected by sampling depth (see supplement).  Our estimates of at least 14-
15 T/F viruses based on env and pol analyses are in good agreement. 
 
Mathematical Modeling of T/F Sequence Evolution 
Sequence lineages with sufficient numbers of sequences for analysis conformed to a model of 
random HIV-1 evolution [4], and we could thus use well-established parameters for HIV-1 reverse 
transcriptase (RT) error rate and virus generation time to estimate the time to a most recent common ancestor 
(MRCA) [8]. Analysis of the most populated T/F lineages in both env and pol revealed far shorter times to an 
estimated MRCA than the 81 days documented clinically.  For example, for gp41 env lineages v1 and v5 
(Fig 1B), the estimated times to a MRCA were 37 and 18 days, respectively; for pol lineages v1 and v2 (Fig 
2B), MRCA estimates were 14 and 23 days (Table S1).  These low MRCA estimates suggest that each 
sequence lineage evolved from a discrete T/F virus that began to replicate only after PEP therapy was 
discontinued.  This finding implies a substantial period of virus sequestration and evolutionary arrest during 
PEP therapy.   
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Drug Resistance Does Not Contribute to Virus Breakthrough 
To determine if transmission of drug resistant viruses or selection for drug resistance could have 
contributed to PEP failure, we analyzed all sequences from the index and source patients for genotypic 
evidence of antiretroviral resistance.  In the RT gene, a K103N mutation was detected in all source and index 
patient sequences (Fig. S1A).  This mutation could be explained by the source patient’s prior therapy but is 
irrelevant to the PEP regimen administered to the HCW.  In protease, the HCW sequences contained a single 
M46I mutation in only one of 15 T/F lineages (2 of 72 sequences total; see variant 15 in Fig 2).  Importantly, 
M46I confers resistance to protease inhibitors only in combination with other resistance-associated mutations 
[9]. Thus, drug resistance mutations relevant to the prescribed PEP regimen were neither transmitted nor 
evolved during or after the administration of PEP.  
 
DISCUSSION 
Understanding molecular mechanisms of HIV-1 prophylaxis failure has important implications for 
public health and for the personal health of individuals exposed to HIV-1.  Here, we apply a novel 
experimental strategy for characterizing and discriminating between potential mechanisms of PEP failure.  
Despite timely initiation of a potent three-drug PEP regimen, the HCW demonstrated delayed viremia and 
seroconversion resulting from transmission of at least 15 T/F viruses.  This is the first example of 
occupational HIV-1 exposure and PEP failure where the molecular identities and minimum numbers of 
actual T/F viral genomes responsible for infection have been unambiguously determined.  
 The surprising findings of 15 drug sensitive T/F viruses, together with minimal diversification of 
their progeny and the absence of relevant transmitted or selected drug resistance-associated mutations, 
suggest virus sequestration and associated evolutionary arrest underlying virus breakthrough in this subject.  
Several mechanisms could potentially explain the sequestration and evolutionary stasis of transmitted viral 
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genomes throughout PEP treatment.  These can be divided into (i) pre-integration latency, (ii) post-
integration latency, (iii) incomplete suppression of virus replication, and (iv) virus trapping.  HIV-1 virion-
associated RNA can enter cells and be arrested prior to proviral integration (pre-integration latency), 
however, the lifespan of pre-integration complexes is generally believed to be only a few days, far less than 
the four-week period of PEP in this subject.  Similarly, post-integration latency would require the unlikely 
occurrence of infection of many thousands, if not millions, of CD4+ T-cells in the first hours after virus 
exposure in order to generate the 15 or more latently-infected memory CD4+ T-cells required to explain our 
findings.  A third possibility is low-level viral replication via cell-to-cell spread, which has been postulated 
to be less sensitive to drug suppression than cell-free virus spread [10].  This mechanism also seems unlikely 
given the evolutionary stasis and absence of accumulated resistance mutations in our 15 T/F virus lineages.  
A fourth possibility, which we favor, is virus trapping and sequestration by follicular dendritic cells (FDCs) 
or other antigen presenting cells.  The initial WB immunoreactivity to gp160 (only) is consistent with this 
hypothesis.  FDCs are known to bind and retain infectious HIV-1 in the form of immune complexes for at 
least 9 months in murine models following footpad inoculation.  Such virus can prime B-cells for antibody 
production and initiate productive virus infection upon co-culture of FDCs and permissive human CD4+ T 
cells [11].   
The literature contains many reports of combination PEP failure in occupational exposures in 
resource-rich countries.  Notably, the majority of these HCWs also experienced significant delays in 
symptoms of acute retroviral syndrome (mean 46, range 23-79 days) and antibody seroconversion (mean 67, 
range 23-97 days) [12].  Because clinical symptoms and systemic viremia typically develop within 10 days 
(95% CI 7-21 days) of virus exposure [3], this protracted time course suggests a scenario similar to our case, 
where exponential virus replication began after completion of PEP.  Similar delays in viremia and antibody 
seroconversion were observed in macaque studies where tenofovir-based PEP failed to protect against 
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intravenous inoculation [13]. Thus delayed viremia, clinical symptoms and antibody seroconversion may be 
common in HIV infection arising after failed PEP.  
The remarkably high numbers of T/F genomes seen in this case have not been observed in sexual 
transmission of HIV-1 [4], nor in the majority of transmissions in injection drug users (IDUs) [6].   The high 
numbers of T/F viruses in the index case, however, are indistinguishable from what has been observed in a 
minority of acutely-infected IDUs and in rhesus macaques inoculated intravenously with simian 
immunodeficiency virus [6, 14].  Thus, while surveys of occupational HIV-1 exposures estimate a low risk 
of virus acquisition following percutaneous exposure (0.3%) [15], with currently available PEP regimens 
further diminishing this risk [2], there may be atypical exposures like the described HCW where the risk of 
virus acquisition is particularly high.  In such cases, more prolonged therapy with potent combination 
antiretroviral therapy may be warranted.   
In summary, we have demonstrated the utility of SGS and T/F virus analyses to distinguish potential 
molecular mechanisms of PEP failure.  Future clinical trials of PEP and PrEP by may benefit from a SGS 
approach to the elucidation of mechanisms of virus breakthrough and treatment failure. 
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Figure Legends 
Figure 1. NJ and ML phylogenies of HIV-1 gp41 env sequences.   A. NJ phylogeny of SGS-derived gp41 
env sequences from the chronically-infected source patient’s plasma vRNA reveals unstructured wide 
genetic diversity typical of chronic HIV-1 infection.  B. NJ phylogeny of SGS-derived sequences from the 
acutely-infected index subject’s plasma vRNA and PBMC DNA reveals multiple low diversity lineages 
typical of acute HIV-1 infection shown in blue (variants 1-14) as well as interspersed interlineage 
recombinant sequences shown in orange. Sequences derived from PBMCs are indicated with asterisks.  C. 
ML phylogeny of sequences from the source patient (in black) and the 14 T/F consensus genomes from the 
index subject (in blue) intersperse within a monophyletic lineage separate from all reference sequences (in 
gray), including Subtype B sequences from Australia.  Scale bars indicate nucleotide distance.  
 
Figure 2. NJ phylogenetic tree and Highlighter plot analysis of pol sequences.  A. NJ phylogeny of SGS-
derived pol sequences from the chronically-infected source patient’s plasma vRNA displaying long branch-
lengths, with the exception of the single cluster of closely related sequences.  Such sequence clusters of near-
identity have been reported as minor components of chronically-infected patients’ plasma virus quasispecies 
and reflect recent clonal expansion of a virus within a diverse chronic virus swarm [7].   B. NJ phylogeny of 
SGS-derived pol sequences from the acutely-infected index subject’s plasma vRNA reveals multiple low 
diversity lineages shown in blue (variants 1-15) as well as interspersed interlineage recombinant sequences 
shown in orange.  C. A Highlighter plot of index case pol sequences represents as colored tics the nucleotide 
polymorphisms between the top sequence (43715D4) and the remaining pol sequences aligned below.  The 
plot illustrates the homology of each of the T/F lineages (in blue), the heterogeneity between T/F lineages, 
and the chimeric structure of the recombinant sequences (in orange).  
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